ASH 2022 | Emerging treatment strategies for patients with high-risk follicular lymphoma
Jeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, discusses emerging treatment options for patients with follicular lymphoma (FL). Dr Abramson explains that while the prognosis of patients with FL has improved over the years, some patients with high-risk disease may progress earlier or be resistant to treatment. To conclude, Dr Abramson further highlights the important role of CAR-T cells and bispecific antibodies in the FL treatment landscape. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS, Seattle Genetics: Research Funding; BMS, AbbVie, Genentech, Epizyme, BeiGene, Kymera, Bluebird Bio, Incyte, Kite Pharma, Genmab, Ono Pharma, Mustang Bio, MorphoSys, Regeneron, Century, AstraZeneca, Lilly, Janssen: Consultancy.
